WO2004069242A1 - Composition anthelmintique - Google Patents
Composition anthelmintique Download PDFInfo
- Publication number
- WO2004069242A1 WO2004069242A1 PCT/AU2004/000126 AU2004000126W WO2004069242A1 WO 2004069242 A1 WO2004069242 A1 WO 2004069242A1 AU 2004000126 W AU2004000126 W AU 2004000126W WO 2004069242 A1 WO2004069242 A1 WO 2004069242A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- composition
- levamisole
- amount
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 230000000507 anthelmentic effect Effects 0.000 title abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 63
- 238000011282 treatment Methods 0.000 claims abstract description 59
- 150000001556 benzimidazoles Chemical class 0.000 claims abstract description 40
- 150000002596 lactones Chemical class 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 35
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical class C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 claims abstract description 34
- 244000045947 parasite Species 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 14
- 230000002195 synergetic effect Effects 0.000 claims abstract description 10
- 241001494479 Pecora Species 0.000 claims description 53
- JMPFSEBWVLAJKM-UHFFFAOYSA-N N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide Chemical compound ClC=1C=C(NC(=O)C=2C(=C(I)C=C(I)C=2)O)C(C)=CC=1C(C#N)C1=CC=C(Cl)C=C1 JMPFSEBWVLAJKM-UHFFFAOYSA-N 0.000 claims description 48
- 229950004178 closantel Drugs 0.000 claims description 48
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 33
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 claims description 33
- 229960001614 levamisole Drugs 0.000 claims description 33
- 229960002669 albendazole Drugs 0.000 claims description 31
- 238000009472 formulation Methods 0.000 claims description 31
- 239000005660 Abamectin Substances 0.000 claims description 23
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims description 22
- 229950008167 abamectin Drugs 0.000 claims description 22
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 18
- 241000243974 Haemonchus contortus Species 0.000 claims description 18
- 241000243976 Haemonchus Species 0.000 claims description 17
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 16
- 229960002418 ivermectin Drugs 0.000 claims description 16
- 241001126268 Cooperia Species 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 8
- 241000243796 Trichostrongylus colubriformis Species 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 241000242711 Fasciola hepatica Species 0.000 claims description 5
- 241000191771 Teladorsagia circumcincta Species 0.000 claims description 4
- 239000002270 dispersing agent Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 241000931178 Bunostomum Species 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 230000003139 buffering effect Effects 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 208000006275 fascioliasis Diseases 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 241000282849 Ruminantia Species 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000008119 colloidal silica Substances 0.000 claims description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims description 2
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000004540 pour-on Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 150000004040 pyrrolidinones Chemical class 0.000 claims description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- -1 lactone compound Chemical class 0.000 claims 66
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims 24
- 229950000975 salicylanilide Drugs 0.000 claims 15
- YWDWYOALXURQPZ-CYBMUJFWSA-N 2-methyl-n-[3-[(6s)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazol-6-yl]phenyl]propanamide Chemical compound CC(C)C(=O)NC1=CC=CC([C@@H]2N=C3SCCN3C2)=C1 YWDWYOALXURQPZ-CYBMUJFWSA-N 0.000 claims 12
- YRWLZFXJFBZBEY-UHFFFAOYSA-N N-(6-butyl-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCCC1=CC=C2N=C(NC(=O)OC)NC2=C1 YRWLZFXJFBZBEY-UHFFFAOYSA-N 0.000 claims 12
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 claims 12
- AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 claims 12
- 229950000536 butamisole Drugs 0.000 claims 12
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 claims 12
- 239000006013 carbendazim Substances 0.000 claims 12
- 229940000188 cydectin Drugs 0.000 claims 12
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims 12
- 229960003997 doramectin Drugs 0.000 claims 12
- 229960005473 fenbendazole Drugs 0.000 claims 12
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 claims 12
- 229960004500 flubendazole Drugs 0.000 claims 12
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 claims 12
- 229960003439 mebendazole Drugs 0.000 claims 12
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 claims 12
- 229960004816 moxidectin Drugs 0.000 claims 12
- 229960001920 niclosamide Drugs 0.000 claims 12
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims 12
- 229960002762 oxibendazole Drugs 0.000 claims 12
- 229950007337 parbendazole Drugs 0.000 claims 12
- 229960000996 pyrantel pamoate Drugs 0.000 claims 12
- 229960004546 thiabendazole Drugs 0.000 claims 12
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims 12
- 239000004308 thiabendazole Substances 0.000 claims 12
- 235000010296 thiabendazole Nutrition 0.000 claims 12
- WKEDVNSFRWHDNR-UHFFFAOYSA-N salicylanilide Chemical class OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 claims 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 3
- 241001147669 Dictyocaulus viviparus Species 0.000 claims 2
- 241000882878 Nematodirus filicollis Species 0.000 claims 2
- 241000882880 Nematodirus spathiger Species 0.000 claims 2
- 241001673868 Oesophagostomum columbianum Species 0.000 claims 2
- 241000893168 Oesophagostomum venulosum Species 0.000 claims 2
- 241000543819 Oestrus ovis Species 0.000 claims 2
- 241000731783 Strongyloides papillosus Species 0.000 claims 2
- 241000122945 Trichostrongylus axei Species 0.000 claims 2
- 241000122858 Trichostrongylus vitrinus Species 0.000 claims 2
- 241000344768 Trichuris ovis Species 0.000 claims 2
- 241000893174 Chabertia ovina Species 0.000 claims 1
- 241000410074 Festuca ovina Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 235000013601 eggs Nutrition 0.000 description 49
- 230000001418 larval effect Effects 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 13
- 241000243797 Trichostrongylus Species 0.000 description 11
- 241000244206 Nematoda Species 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 241000510960 Oesophagostomum Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 description 5
- 241001137882 Nematodirus Species 0.000 description 5
- 229960003734 levamisole hydrochloride Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 241000243795 Ostertagia Species 0.000 description 4
- 241000347415 Teladorsagia Species 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 150000003278 haem Chemical class 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 244000144992 flock Species 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 229940007210 ivomec Drugs 0.000 description 2
- 230000003108 parasitologic effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229940112705 valbazen Drugs 0.000 description 2
- 241000893172 Chabertia Species 0.000 description 1
- 241001147667 Dictyocaulus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 241000244174 Strongyloides Species 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Definitions
- This invention relates to the treatment of anthelmintic infections in animals, and more particularly to compositions that are effective against parasites that are resistant to a wide variety of drug treatments, particularly in non-human animals..
- Farm animals such as lambs, weaners and sheep may typically be infected by a wide variety of parasites.
- parasites include Haemonconchus spp., Ostertagia spp., Trichostrongylus spp., Cooperia spp., Nematodirus spp., Chabertia spp., Oesophagostomum spp., Trichuris spp., Strongyloides spp., Bunostomum spp., Oestrus spp., Dictyocaulus spp., Fasciola spp. and Monezia spp. Specific examples of these parasites are set out in Table 1.
- the present invention provides in a first aspect, a synergistic anthelmintically effective composition consisting of at least one compound selected from each of the following groups: macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles and a therapeutically acceptable carrier.
- the present invention provides a method for treating parasitic infections in an animal, comprising administering to the animal, a synergistic anthelmintically effective amount of a composition which consists of at least one compound selected from each of the following groups: macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles and a therapeutically acceptable carrier.
- the present invention further provides the use of a synergistic anthelmintically effective amount of a composition which consists of at least one compound selected from each of the following groups: macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles and a therapeutically acceptable carrier in the treatment of a parasitic infection in an animal.
- the aforementioned treatments may be desirably administered to animals prior to introduction to a land area so as to prevent the land area from becoming infested with parasites which may or may not be resistant to one or more compounds selected from the groups consisting of macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles.
- animals such as sheep, will be isolated for at least 2 days after treatment before being placed on pasture.
- animals may be treated at any time, as appropriate, particularly when it is suspected that the animal may be carrying at least one parasite which is resistant to at least one of the groups macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles.
- compositions of this invention have application where the parasites are resistant to known drug treatments.
- the compositions are effective in situations where parasites are resistant to at least one of each of the groups macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles.
- the compositions are effective in situations where parasites are resistant to at least two of each of the groups macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles.
- the compositions are effective in situations where parasites are resistant to at least three of each of the groups macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles.
- the compositions are effective in situations where parasites are resistant to all of the groups macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles.
- a preferred indication is the treatment of stock to eliminate adult gastro- intestinal worms and liver fluke.
- treatment results in the clearance of >95% of total worm count including worms resistant to at least one of each of the groups macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles.
- Compositions of this invention include at least one compound selected from each of the groups: macrocylic lactones, benzimidazoles, salicylanilides and imidazothiazoles.
- the therapeutically active compounds used in the invention are preferably incorporated into formulations in the range of concentrations as follows (g/L)
- macrocylic lactones 0.1-20.0 g/L, preferably 0.5-1.5 g/L benzimidazoles: 1-100 g/L, preferably 18-30 g/L salicylanilides: 1-100 g/L, preferably 30-50 g/L imidazothiazoles: 1 -100 g L, preferably 30-50 g L
- drenches are preferred dosage forms for the compositions of this invention, a number of alternative compositions may be used. These pour-on transdermals, slow release boluses for rumenal deposition and injectable formulations. Each dosage form requires a therapeutically effective carrier.
- a formulation will include a solvent system for the macrocylic lactones, one or more dispersing and suspending agents for the benzimidazoles and salicylanilides , one or more surfactants, one or more preservatives, a buffering system and water as a carrier.
- the solvent system for the macrocyclic lactones includes at least one solvent selected from the group consisting of: polyethylene glycol, tetraglycol, ethanol, benzyl alcohol and propylene glycol.
- the dispersing and suspending agents for the benzimidazoles and salicylanilides include at least one selected from the group consissting of: glyceryl palmitostearate, bentonite, colloidal silica, xanthan gum and polymeric pyrrolidones.
- Surfactants that may be used include polysorbate 80 and ethoxylated castor oil.
- buffer systems may be used, particularly phosphate buffers based on combinations of varying amounts of monobasic and dibasic sodium phosphate to achieve the desired pH.
- compositions of the invention are effective when used in a variety of animals.
- animals For example, sheep, goats, ruminants (including cattle) and camelids.
- Example 4 was prepared as follows:
- step 1. Add polysorbate 80 to step 1. 3. Add water to the solution from step 2 and mix until homogeneous.
- Trial RD0201-H002 A critical pen sacrifice study evaluating the therapeutic efficacy of a combination abamectin. levamisole hvdrochloride, albendazole and closantel anthelmintic formulation against resistant strains of Haemonchus contortus, Trichostrongylus colubriformis and Teladorsasia circumcincta in sheep.
- faecal samples were collected from each trial animal to confirm individual zero faecal egg counts. Later that day trial sheep were infected with approximately 5000 Haemonchus contortus (macrocyclic lactone and closantel resistant strains), 6000 Trichostrongylus colubriformis (levamisole hydrochloride and albendazole resistant strains) and 5000 Osteratagia circumcincta (macrocyclic and albendazole resistant strains) infective larvae. Faecal samples were collected from each sheep on 14 th June 2002 (Day -3) and individual faecal egg counts were conducted.
- Animals were ranked on the basis of decreasing faecal egg counts and blocked into eight blocks each of two animals and randomly allocated to the treatment groups from these blocks. The 16 animals with the highest counts were selected for inclusion in the trial and the two animals with the lowest faecaLegg counts were selected as spare animals.
- the 18 trial sheep (including the 2 spare animals) were sacrificed on 27 th June 2002 (Day 10) for collection of faecal samples, abomasal and small intestine contents. Individual faecal egg counts, treatment group coprocultures and total worm counts were conducted for calculation of treatment efficacies.
- Drenchrites (CSIRO Research - Horizon Technology 1996) was performed between the 10 th July and the 23 rd August 2002 to clarify that strains of Trichostrongylus colubriformis used were resistant to levamisole hydrochloride and albendazole and, Osteratagia circumcincta were resistant to albendazole.
- Example 4 abamectin / closantel /albendazole /levamisole hydrochloride
- Table 10 Larval differentiation results followin rou bulk co roculture- Larvae as a % of the total number counted.
- Example 4 Excellent control (>99.9% reduction) was achieved by the Example 4 formulation against the major nematodes, macrocyclic lactone and closantel resistant strains of Haemonchus spp. (adult and immature stages - geometric means), macrocyclic and albendazole resistant strains Ostertagia spp. (adult, immature and L4 stages - geometric means) and levamisole hydrochloride and albendazole resistant strains of Trichostrongylus spp (adult and immature stages - geometric means) as assessed by geometric total worm counts.
- Trial JUA1240r A property faecal egg count reduction study evaluating the therapeutic efficacy of the Example 4 formulation against field strains of mixed nematode population of either Haemonchus contortus, Trichostrongylus colubriformis and/or Teladorsagia circumcincta in sheep.
- the aim of this field study was to study and evaluate under field conditions, the therapeutic efficacy of Example 4 when administered to sheep that are known to be harbouring resistant strains of nematodes.
- the selected trial site was known to harbour closantel resistant Haemonchus contortus. This however was not confirmed during the initial phase of the study as a full dose of closantel was admimstered (as stated in the protocol).
- Standard industry practice for diagnosis of closantel resistance in the field involves either the administration of a full dose of closantel and sequential sampling of treated sheep over three to six weeks post treatment, or alternatively administration of a 1/3 dose and sampling at 10 to 14 days post treatment.
- a second faecal egg count reduction study was conducted after consultation with the Study Sponsor to confirm the closantel resistance status at the trial site, "Kelvin East".
- the second phase of the study involved two groups of sheep each consisting of ten animals. Ten random faecal samples were collected prior to treatment from the mob of wethers to confirm a nematode burden of greater than 400 eggs/gram, and a group coproculture that confirmed a very high percentage (91%) of Haemonchus contortus were present.
- Treatment Day Day 0
- individual faecal samples were collected from twenty animals as they presented in the race. These animals were weighed and weights recorded and treatments administered in accordance to the treatment regime (detailed in Table 12). Faecal samples were returned to Veterinary Health Research for individual faecal egg counts and group coprocultures. Animals were observed post treatment for adverse reactions. None were detected.
- Table 14 Group arithmetic mean faecal egg counts and body weights at Day 0.
- Table 15 Group arithmetic and geometric mean faecal egg counts (epg).
- Table 16 Overall percentage efficacy calculated using arithmetic and geometric group mean faecal egg counts.
- Table 20 Group arithmetic mean faecal egg counts and body weights at Day 0.
- Table 21 Group arithmetic and geometric mean faecal egg counts.
- Table 23 Nematode population % - Pre-trial, Day 0 and Day 11 (based on faecal culture and larval differentiation).
- the second faecal egg count reduction test was to confirm the presence closantel resistant Haemonchus at the trial site. This was achieved by administering a one third dose of closantel to a group of ten (10) animals and the addition of another group often (10) animals retained as untreated controls.
- the use of a one third dose of closantel is standard industry practice for diagnosis of closantel resistance in the field. Reduced efficacy of closantel was observed against Haemonchus, confirming. The presence of closantel resistant Haemonchus at the trial site.
- Example 4 Excellent efficacy (> 99.0%) was attained by the Example 4 formulation against a mixed gastrointestinal population including closantel resistant Haemonchus as well as levamisole and benzimidazole resistant Trichostrongylus.
- Trial JUA1273r A property faecal egg count reduction study evaluating the therapeutic efficacy of the Example 4 formulation against field strains of mixed nematode populations, including closantel resistant strains of Haemonchus contortus in sheep.
- Trial sheep had already been identified Using uniquely numbered ear tags as part of standard farming practice at the trial site. From the ninety (90) potential trial sheep sixty (60) sheep were selected and allocated (according to individual strongyle faecal egg counts) to six (6) groups of ten (10) sheep each, such that each group had a similar group arithmetic mean strongyle faecal egg count and range of faecal egg counts within the group.
- Trial sheep in Group 2 were treated according to individual body weight with the test formulation, trial sheep in Groups 3-6 were treated with the respective reference formulation and trial sheep in Group 1 were retained untreated as negative controls.
- Groups 2, 3, 5 and 6 were treated at the recommended dose rate for each active, while sheep in Group 4 were treated at one third the normal closantel dose rate, to determine and demonstrate the presence of closantel resistance (Reference: Rolfe PF; Fourth International Congress for Sheep Veterinarians 1997, pg 55). Sheep were observed in the immediate post-treatment period for adverse reactions (none were observed). Individual strongyle faecal egg counts and group bulk coprocultures for larval differentiation were subsequently performed on the samples collected. Trial sheep were returned to the sheep yards on Day 13 of the trial (1 st October 2002) and individual faecal samples again collected. All trial sheep received a single therapeutic dose of Rycozole® 1 due to animal welfare concerns. Individual strongyle faecal egg counts and group bulk coprocultures for larval differentiation were subsequently performed on the samples collected.
- Treatment efficacies were then calculated using group arithmetic and geometric strongyle faecal egg counts for the major strongyle species present (see figures 8 and 9 and note that the treatment "Jurox" refers to treatment with Example 4).
- Table 26 Group arithmetic mean, maximum and minimum strongyle faecal egg counts and standard deviations following allocation.
- Table 29 Group Arithmetic and Geometric Mean strongyle faecal egg counts during the trial (excluding Nematodirus spp.)
- Table 30 Larval differentiation results from group bulk coprocultures.
- Table 31 Overall treatment efficacies, against all strongyle species (apart from Nematodirus s .
- Efficacies attained by the comparison formulations against this strain of Haemonchus contortus ranged from 85.5% for the albendazole formulation (Valbazen®) through 96.1% for the ivermectin formulation (Ivomec®) to 99.8% for the levamisole formulation (Levamisole®), based on group arithmetic mean faecal egg counts and larval differentiation. Efficacies attained against this strain based on geometric mean faecal egg counts and larval differentiation were 84.9%, 97.5% and >99.9% for these formulations respectively.
- Treatment with a 1/3 dose of closantel resulted in a treatment efficacy of 83.0% based on arithmetic group mean faecal egg counts and a treatment efficacy of 86.8% based on geometric group mean faecal egg counts, confirming the presence of moderate closantel resistance by this Haemonchus strain.
- Insufficient numbers of other gastrointestinal strongyles Nematodirus, Teolodorsagia and Trichostrongylus species were present to draw any conclusions about efficacy of the test formulation against these strains.
- Trial JUA1270r A property faecal egg count reduction study evaluating the therapeutic efficacy of the Example 4 formulation against field strains of mixed nematode populations, including macrocyclic lactone resistant strains of Haemonchus contortus in sheep in sheep.
- Treatment efficacies were then calculated using group arithmetic and geometric strongyle faecal egg counts for the major strongyle species present (see figures 11 and 12 and note that the treatment "Jurox" refers to treatment with Example 4).
- Table 33 Treatment table.
- Table 34 Grou arithmetic mean, maximum and minimum stron le faecal e counts and standard deviations followin allocation.
- Table 37 Group Arithmetic and Geometric Mean strongyle faecal egg counts during the trial.
- Haemonchus spp. Trichostrongylus spp., "Cooperia spp., Oesophagostomum spp
- Table 39 Treatment efficacies against Haemonchus contortus.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0407271A BRPI0407271B1 (pt) | 2003-02-05 | 2004-02-04 | composição anti-helmíntica |
AU2004210461A AU2004210461C1 (en) | 2003-02-05 | 2004-02-04 | Anthelmintic composition |
NZ540391A NZ540391A (en) | 2003-02-05 | 2004-02-04 | Anthelmintic composition |
GB0516881A GB2413764B8 (en) | 2003-02-05 | 2004-02-04 | Anthelmintic compostion |
AU2009201942A AU2009201942C1 (en) | 2003-02-05 | 2009-05-15 | Anthelmintic composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003900505A AU2003900505A0 (en) | 2003-02-05 | 2003-02-05 | Anthelmintic composition |
AU2003900505 | 2003-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004069242A1 true WO2004069242A1 (fr) | 2004-08-19 |
Family
ID=30005205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2004/000126 WO2004069242A1 (fr) | 2003-02-05 | 2004-02-04 | Composition anthelmintique |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR043044A1 (fr) |
AU (3) | AU2003900505A0 (fr) |
BR (1) | BRPI0407271B1 (fr) |
GB (1) | GB2413764B8 (fr) |
NZ (1) | NZ540391A (fr) |
WO (1) | WO2004069242A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2403905A (en) * | 2003-07-12 | 2005-01-19 | Norbrook Lab Ltd | Parasiticidal composition |
WO2009004432A1 (fr) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | Combinaison anthelminthique |
WO2009060063A1 (fr) * | 2007-11-09 | 2009-05-14 | Intervet International B.V. | Combinaison anthelminthique |
WO2011027333A1 (fr) * | 2009-09-07 | 2011-03-10 | Douglas Robert Cleverly | Préparations anthelmintiques granulées |
WO2011143479A1 (fr) * | 2010-05-12 | 2011-11-17 | Merial Limited | Formulations parasiticides injectables de lévamisole et de lactones macrocycliques |
AU2010100349B4 (en) * | 2009-04-15 | 2012-03-29 | Jurox Pty Ltd | Anthelmintic formulation |
WO2013030702A2 (fr) | 2011-08-16 | 2013-03-07 | Virbac Sa | Formulations et traitements anthelminthiques |
US9198430B2 (en) | 2011-06-23 | 2015-12-01 | Bayer New Zealand Limited | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
WO2018038623A1 (fr) * | 2016-08-23 | 2018-03-01 | Donaghys Limited | Améliorations apportées à des traitements de parasites |
RU2774960C2 (ru) * | 2017-08-04 | 2022-06-24 | Байер Энимэл Хельс ГмбХ | Хинолиновые производные для лечения инфекций, вызванных гельминтами |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060380A1 (fr) * | 2000-02-16 | 2001-08-23 | Phoenix Scientific, Inc. | Formulation antiparasitaire et procede de fabrication de cette formulation |
-
2003
- 2003-02-05 AU AU2003900505A patent/AU2003900505A0/en not_active Abandoned
-
2004
- 2004-02-04 GB GB0516881A patent/GB2413764B8/en not_active Expired - Lifetime
- 2004-02-04 WO PCT/AU2004/000126 patent/WO2004069242A1/fr active Application Filing
- 2004-02-04 NZ NZ540391A patent/NZ540391A/en unknown
- 2004-02-04 AU AU2004210461A patent/AU2004210461C1/en not_active Expired
- 2004-02-04 BR BRPI0407271A patent/BRPI0407271B1/pt active IP Right Grant
- 2004-02-05 AR ARP040100372A patent/AR043044A1/es unknown
-
2009
- 2009-05-15 AU AU2009201942A patent/AU2009201942C1/en not_active Expired
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060380A1 (fr) * | 2000-02-16 | 2001-08-23 | Phoenix Scientific, Inc. | Formulation antiparasitaire et procede de fabrication de cette formulation |
Non-Patent Citations (1)
Title |
---|
LOUW J.P. ET AL., JL.S.AFR.VET.ASS., vol. 64, no. 2, 1993, pages 71 - 75 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2403905B (en) * | 2003-07-12 | 2005-12-14 | Norbrook Lab Ltd | Parasiticidal composition |
GB2403905A (en) * | 2003-07-12 | 2005-01-19 | Norbrook Lab Ltd | Parasiticidal composition |
US8993546B2 (en) | 2003-07-12 | 2015-03-31 | Norbrook Laboratories Limited | Parasiticidal composition |
WO2009004432A1 (fr) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | Combinaison anthelminthique |
US8440633B2 (en) | 2007-06-29 | 2013-05-14 | Ah Usa 42 Llc | Anthelmintic combination |
AU2008272646B2 (en) * | 2007-06-29 | 2013-08-22 | Zoetis Services Llc | Anthelmintic combination |
WO2009060063A1 (fr) * | 2007-11-09 | 2009-05-14 | Intervet International B.V. | Combinaison anthelminthique |
AU2010100349B4 (en) * | 2009-04-15 | 2012-03-29 | Jurox Pty Ltd | Anthelmintic formulation |
AU2020202781B2 (en) * | 2009-09-07 | 2021-05-13 | Argenta Innovation Limited | Granulated anthelmintic preparations and delivery systems |
WO2011027333A1 (fr) * | 2009-09-07 | 2011-03-10 | Douglas Robert Cleverly | Préparations anthelmintiques granulées |
AU2022200149B2 (en) * | 2009-09-07 | 2023-06-15 | Argenta Innovation Limited | Granulated anthelmintic preparations and delivery systems |
US11253593B2 (en) | 2009-09-07 | 2022-02-22 | Argenta Innovation Limited | Granulated anthelmintic preparations and delivery systems |
AU2011252987B2 (en) * | 2010-05-12 | 2013-05-02 | Boehringer Ingelheim Animal Health USA Inc. | Injectable parasiticidal formulations of levamisole and macrocyclic lactones |
WO2011143479A1 (fr) * | 2010-05-12 | 2011-11-17 | Merial Limited | Formulations parasiticides injectables de lévamisole et de lactones macrocycliques |
US9198430B2 (en) | 2011-06-23 | 2015-12-01 | Bayer New Zealand Limited | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
EP2744495B1 (fr) | 2011-08-16 | 2017-01-18 | Virbac | Composition antihelmintique et traitements |
WO2013030702A2 (fr) | 2011-08-16 | 2013-03-07 | Virbac Sa | Formulations et traitements anthelminthiques |
WO2018038623A1 (fr) * | 2016-08-23 | 2018-03-01 | Donaghys Limited | Améliorations apportées à des traitements de parasites |
RU2774960C2 (ru) * | 2017-08-04 | 2022-06-24 | Байер Энимэл Хельс ГмбХ | Хинолиновые производные для лечения инфекций, вызванных гельминтами |
Also Published As
Publication number | Publication date |
---|---|
AU2004210461B2 (en) | 2009-12-03 |
AU2009201942C1 (en) | 2017-06-29 |
AU2009201942A1 (en) | 2009-06-04 |
GB2413764B (en) | 2006-12-20 |
GB2413764A8 (en) | 2013-10-16 |
GB2413764A (en) | 2005-11-09 |
AR043044A1 (es) | 2005-07-13 |
AU2009201942B2 (en) | 2012-02-16 |
BRPI0407271B1 (pt) | 2015-11-10 |
GB2413764B8 (en) | 2013-10-16 |
BRPI0407271A (pt) | 2006-01-31 |
AU2004210461C1 (en) | 2017-06-29 |
NZ540391A (en) | 2006-12-22 |
AU2003900505A0 (en) | 2003-02-20 |
GB0516881D0 (en) | 2005-09-28 |
AU2004210461A1 (en) | 2004-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009201942B2 (en) | Anthelmintic composition | |
JP2007008963A (ja) | 表面殺寄生生物処方物および処置方法 | |
JP5342239B2 (ja) | ベンジイミダゾール非水性組成物 | |
CN106132409B (zh) | 稳定的兽用驱虫制剂 | |
Waruiru | Efficacy of closantel, albendazole and levamisole on an ivermectin resistant strain of Haemonchus contortus in sheep | |
Vickers et al. | Resistance to macrocyclic lactone anthelmintics by Haemonchus contortus and Ostertagia circumcincta in sheep in New Zealand | |
AU2010100349A4 (en) | Anthelmintic formulation | |
Waller et al. | Resistance of Trichostrongylus colubriformis to levamisole and morantel: differences in relation to selection history | |
Stevenson et al. | The efficacy of formulations of triclabendazole and ivermectin in combination against liver fluke (Fasciola hepatica) and gastro‐intestinal nematodes in cattle and sheep and sucking lice species in cattle | |
AU2012200544C1 (en) | Anthelmintic composition | |
KR101233488B1 (ko) | 구충 제형 | |
JP2966530B2 (ja) | 恒温動物の体内および体外寄生虫の防除用に有効な注ぎ調剤及びその使用方法 | |
Gogolewski et al. | Control of gastro-intestinal parasitism in sheep with ivermectin delivered via an intraruminal controlled-release capsule | |
US11938103B2 (en) | Potentiation of helminth treatment | |
Bisset et al. | An evaluation of an oral formulation of moxidectin against selected anthelmintic-resistant and-susceptible strains of nematodes in lambs | |
NZ515772A (en) | Pesticidal emulsion composition containing levamisole in the aqueous phase and an anthelmintic in the organic phase | |
Kates et al. | Helminth control in grazing sheep: periodic treatment with levamisole, morantel, cambendazole, and mebendazole | |
Kumar et al. | Comprehensive control of GI helminths and mite infestation in growing piglets with chemical and herbal anthelmintic and miticides packages | |
JP2023507116A (ja) | 蠕虫治療の相乗作用 | |
OA19425A (en) | Veterinary compositions and the uses thereof for preventing and/or treating parasitic infections in non-human mammals. | |
AU2003275779A1 (en) | Topical parasiticide formulations and methods of treatment | |
Sargison | New worming guidelines: Quarantine anthelmintic treatments | |
Chaudhri et al. | Anthelmintic efficiency of a benzimidazole carbamate compound against certain gastrointestinal nematodes of sheep, crossbred calves, poultry and its comparison to fenbendazole | |
ES2416004A1 (es) | Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004210461 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 540391 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2004210461 Country of ref document: AU Date of ref document: 20040204 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004210461 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 0516881 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20040204 |
|
ENP | Entry into the national phase |
Ref document number: PI0407271 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |